Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Letter to the Editor

Volume 9, Number 12, December 2017, pages 1029-1031


The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4

Figure

Figure 1.
Figure 1. Clinical course. Cre: creatinine; eGFR: estimated glomerular filtration rate.

Table

Table 1. Possible Mechanisms for Renal Protective Effects of SGLT2 Inhibitors
 
1. Reduced blood pressure, arterial stiffness and vascular resistance [15, 16]
2. Decrease in glomerular hyperfiltration [17]
3. Decrease in intraglomerular pressure [18]
4. Reduction in serum uric acid levels [5]
5. Utilization of ketone bodies by failing kidney/heart [19]
6. Improvement in tubulointerstitial hypoxia [20]
7. Increase of erythropoietin [21]
8. Improvement in renal fucntion due to improved cardiac function